ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Bristol-Myers Squibb Co’s Profitability and Valuation Ratios Bristol-Myers Squibb Co’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 17.58% ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

A pharmaceutical giant that made a splashy, incentive-backed entrance to Tampa over 10 years ago plans to slash its office ...

Bristol Myers Squibb Co. closed $9.72 below its 52-week high ($59.46), which the company reached on September 21st.

Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.